Home

NASDAQ:BCYC Stock Quote

7.8500
+0.00 (0.00%)

Bicycle Therapeutics is a biopharmaceutical company that focuses on creating groundbreaking therapeutic treatments using its proprietary bicycle technology platform

This innovative platform generates a new class of medicines known as bicyclic peptides, which are designed to deliver targeted therapies for various diseases, including cancer and other serious conditions. The company’s research and development efforts aim to enhance the efficacy and safety of treatments by leveraging the unique properties of these cyclic peptide compounds, thus addressing unmet medical needs in the pharmaceutical landscape. Through collaboration with industry partners and ongoing clinical trials, Bicycle Therapeutics strives to advance its pipeline of potential drug candidates toward commercialization.

SummaryNewsPress ReleasesChartHistoricalFAQ
Deep Dive Into Bicycle Therapeutics Stock: Analyst Perspectives (9 Ratings)benzinga.com
Via Benzinga · February 26, 2025
Forecasting The Future: 11 Analyst Projections For Bicycle Therapeuticsbenzinga.com
Via Benzinga · January 13, 2025
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · December 18, 2024
Breaking Down Bicycle Therapeutics: 8 Analysts Share Their Viewsbenzinga.com
Via Benzinga · December 16, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 13, 2024
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 13, 2024
Navigating 11 Analyst Ratings For Bicycle Therapeuticsbenzinga.com
Via Benzinga · October 24, 2024
In-Depth Examination Of 5 Analyst Recommendations For Bicycle Therapeuticsbenzinga.com
Via Benzinga · September 6, 2024
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patientsbenzinga.com
Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification.
Via Benzinga · December 13, 2024
BCYC: A Promising Play In The Biotech Sectortalkmarkets.com
The long-awaited and overdue half-point cut in the federal funds rate was the impetus for the SPDR Biotech ETF to finally break above the 102-103 level. Meanwhile, Bicycle Therapeutics Plc. had a strong ESMO following promising new data
Via Talk Markets · October 1, 2024
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tonebenzinga.com
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safety over competitors. The analyst projects ~$2 billion in peak sales by 2033 and sees opportunities beyond metastatic urothelial cancer.
Via Benzinga · September 6, 2024
The Latest Analyst Ratings For Bicycle Therapeuticsbenzinga.com
Via Benzinga · August 7, 2024
BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q2 2024investorplace.com
BCYC stock results show that Bicycle Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024
Expert Ratings For Bicycle Therapeuticsbenzinga.com
Via Benzinga · April 10, 2024
The Analyst Landscape: 4 Takes On Bicycle Therapeuticsbenzinga.com
Via Benzinga · February 21, 2024
Forecasting The Future: 4 Analyst Projections For Bicycle Therapeuticsbenzinga.com
Via Benzinga · December 20, 2023
Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Viewsbenzinga.com
Via Benzinga · May 23, 2024
Gold Falls Sharply; US Composite PMI Surges In Maybenzinga.com
Via Benzinga · May 23, 2024
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursdaybenzinga.com
Via Benzinga · May 23, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 23, 2024
BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q1 2024investorplace.com
BCYC stock results show that Bicycle Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 2, 2024
Walmart To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via Benzinga · February 21, 2024
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · February 13, 2024
Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Fridaybenzinga.com
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today’s session.
Via Benzinga · December 15, 2023
La-Z-Boy Posts Upbeat Earnings, Joins Victoria's Secret, Snowflake And Other Big Stocks Moving Higher On Thursdaybenzinga.com
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 200 points on Thursday.
Via Benzinga · November 30, 2023